Welcome

Exelixis Gets FDA Approval of Cabometyx For Thyroid Cancer

Sept. 17, 2021, 8:32 PM

Exelixis has received U.S. FDA approval of Cabometyx in patients 12 years and older with previously treated radioactive iodine-refractory differentiated thyroid cancer.

  • Approval ahead of PDUFA target date of Dec. 4, 2021
  • Approval based on results from COSMIC-311 trial
  • Co. says it’s prepared to fully support expanded indication immediately
  • Exelixis shares up over 2% in extended trading

To view the source of this information, click here

To contact the reporter on this story:
Cara Moffat in Los Angeles at cmoffat@bloomberg.net

To contact the editor responsible for this story:
Lauren Berry at lberry4@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.